Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.
about
Estrogen receptor alpha gene amplification in breast cancer: 25 years of debateTamoxifen Resistance: Emerging Molecular TargetsThe Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of JanusRevealing the Complexity of Breast Cancer by Next Generation SequencingOptimal management of hormone receptor positive metastatic breast cancer in 2016Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkersAre Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?Antiestrogens: structure-activity relationships and use in breast cancer treatmentSystemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Exome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers.Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.Precision medicine in breast cancer: reality or utopia?Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signalingAcquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populationsEvaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader.The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omicsImmunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy.Estrogen receptor mutations and their role in breast cancer progressionTargeted therapies for ER+/HER2- metastatic breast cancer.Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers.Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal ResistanceLoss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer.Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patientsA decision support framework for genomically informed investigational cancer therapy.Clinical next generation sequencing to identify actionable aberrations in a phase I program.The changing role of ER in endocrine resistance.Endocrine resistance in breast cancer--An overview and update.Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer.Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencingThe molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.
P2860
Q24273274-1B27665A-E6FD-4A98-9ACA-812CEDFA36DAQ26739969-AC721962-3D27-4612-A917-5AAC0446B0E3Q26740184-02110BB0-74AF-44B2-A3F0-0C4F46D23C93Q26777395-D9DA5752-5731-4D81-BBF3-16E91DC94413Q26777683-30A62D5F-AD7B-4BD2-B107-19FF1F9FD981Q28069856-DE7F71E8-5C1C-447A-8FF0-E4CD7D92F063Q28074060-6B609B13-EFA9-4302-A7C8-9C3EDF86C7CCQ28077245-A9EDC37A-E983-41BB-859E-DFCC8DFBBEC2Q30239901-A6349DA9-6B28-47AC-BAF5-1CBBFE627DE0Q30372977-567961C0-AC00-4DA8-8900-6A95F1DC1D57Q33722765-4FECFCF1-0B38-4FEC-9739-538F9405C30FQ33806957-38807069-2408-43F7-875C-7AE491B87ADEQ33809114-C9FDEF3D-D767-4FDC-8F12-A064176CB4A3Q33819404-3F8FD64A-D218-4FCB-8A11-280051845368Q33903949-28E41569-F484-431A-A35A-8FF31CA5C3B2Q34315889-39CD76AF-4CCC-4A8B-8D6A-3AAE05B1FD99Q34484414-93CC88E7-C6EC-41DD-BA09-9C1CEA968FE7Q34534031-EE59E00F-C6C9-479E-AC30-4C26E66D1B2DQ34708926-A47A4805-3E27-4549-96C7-B88956D6549BQ34736075-2755D269-AB5E-4201-8BBF-A222E58BE945Q35025646-1F478E8E-8747-4203-80BB-2E350E75645CQ35159751-6AEA54E7-36B6-4B5A-91C6-1126254246CCQ35599448-725DCDDF-8149-4815-8A71-B85339F0D71FQ35658860-7BA8658C-5064-4FF5-9057-B3821CEE94A6Q35763853-6724A805-E9AF-464D-B168-91001B958600Q36011096-58F18667-CB76-4E64-9FD7-3998B4904A86Q36022154-A00A516F-769D-43A6-9E86-8476B41F15F5Q36047387-9649E6D6-77A8-4F2B-AB04-B56EC26B31B2Q36064901-7867FA82-008C-4E8F-A64B-D5AF95DA6525Q36279700-6C5C863E-4B68-4A70-8367-1267FC617365Q36288939-8B82BD3F-B8D7-40D8-B42A-FA53F08F27C6Q36294743-1DD3BCB1-10B2-454B-ACBB-392632DBFC09Q36299589-FCFC7199-1A9C-4606-9115-0E21C2EEC82EQ36336601-597A1169-A00B-45BB-BBFF-EDA8FA1381B1Q36386322-FFAFD0A8-83F6-4CCA-B518-8DAE8394D30CQ36450456-B76F7A05-D3A8-4D5B-ADC0-C7095883525BQ36545690-7D37C2D5-DD4C-4B51-8993-5BE30E79EAEAQ36598699-6E570E87-01FE-45E7-822E-F8F69E721CDBQ36642923-E8F4B995-BCF5-44D1-AC75-2AE7DB2DED92Q36768079-30CF18D7-6D89-452D-84B6-251778424EC7
P2860
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emergence of constitutively ac ...... ceptor-positive breast cancer.
@en
Emergence of constitutively ac ...... ceptor-positive breast cancer.
@nl
type
label
Emergence of constitutively ac ...... ceptor-positive breast cancer.
@en
Emergence of constitutively ac ...... ceptor-positive breast cancer.
@nl
prefLabel
Emergence of constitutively ac ...... ceptor-positive breast cancer.
@en
Emergence of constitutively ac ...... ceptor-positive breast cancer.
@nl
P2093
P2860
P50
P1476
Emergence of constitutively ac ...... ceptor-positive breast cancer.
@en
P2093
Addie Dvir
Ana Maria Gonzalez-Angulo
Carlos L Arteaga
Doron Lipson
Garrett Frampton
Geoff Otto
Gilles Buchwalter
Jaime Ferrer-Lozano
P2860
P304
P356
10.1158/1078-0432.CCR-13-2332
P407
P577
2014-01-07T00:00:00Z